MedPath

EVALUATION OF THE EFFECT OF ADDING GNRH AGONIST TO THE DUAL PROGESTERONE (INTRAMUSCULAR AND VAGINAL) AS LUTEAL PHASE SUPPORT IN FROZEN-THAWED EMBRYO TRANSFERS DURING ARTIFICIAL CYCLES: A RANDOMIZED CONTROLLED TRIAL.

Not Applicable
Completed
Conditions
Health Condition 1: N979- Female infertility, unspecified
Registration Number
CTRI/2021/09/036421
Lead Sponsor
Angels Fertility Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
120
Inclusion Criteria

a.Patients undergoing IVF/ICSI cycles using FET.

b. Age between 20 to 40 years.

c. Antagonist cycles

d. Given P4 and E2 or P4, E2 plus GnRH agonist as LPS.

e. Written informed consent.

Exclusion Criteria

a. Uterine fibroid if encroaching uterine cavity.

b. Mullerian anomalies.

c. Ovarian endometrioma.

d. Polycystic ovarian syndrome (PCOS).

e. Use of donor sperms or oocytes.

f. Adnexal hydrosalpinx except after disconnection.

g. Allergy to triptorelin.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. To determine Biochemical Pregnancy (Positive urine test or serum �²-HCG50m IU/ml after 14 days of embryo transfer). <br/ ><br>2. To determine Clinical Pregnancy Rate (Presence of gestational sac or fetus heartbeat at 4-weeks after embryo transfer or 6-7 weeks or pregnancy). <br/ ><br>3. To determine implantation rate (Number of gestational sacs divided by the number of embryos transferred). <br/ ><br>4. To determine Ongoing Pregnancy Rate (Pregnancy contouring beyond 12 weeks of pregnancy).Timepoint: 1. To determine Biochemical Pregnancy (Positive urine test or serum �²-HCG50m IU/ml after 14 days of embryo transfer). <br/ ><br>2. To determine Clinical Pregnancy Rate (Presence of gestational sac or fetus heartbeat at 4-weeks after embryo transfer or 6-7 weeks or pregnancy). <br/ ><br>3. To determine implantation rate (Number of gestational sacs divided by the number of embryos transferred). <br/ ><br>4. To determine Ongoing Pregnancy Rate (Pregnancy contouring beyond 12 weeks of pregnancy).
Secondary Outcome Measures
NameTimeMethod
To determine the incidence of OHSSTimepoint: Continious monitoring during the study.;To determine the Miscarriage Rate.Timepoint: Upto 10 weeks of gestation;To determine the Multiple Pregnancy RateTimepoint: Pregnancy with 2/more fetuses;To determine the role of GnRH agonist as LPS agent in FET antagonist IVF/ICSI cycles based on womens age and duration of infertility.Timepoint: At the end of the study.
© Copyright 2025. All Rights Reserved by MedPath